RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	3.71	6.53	61.8	85.76	64.36	6.29
Revenue	3.71	6.53	61.8	85.76	64.36	6.29
Revenue Growth (YoY)	-89.63%	-89.43%	-27.94%	33.25%	923.03%	-24.75%
Cost of Revenue	2.45	3.46	33.34	49.41	36.89	2.26
Gross Profit	1.26	3.07	28.46	36.35	27.47	4.03
Selling, General & Admin	20.97	30.98	64.03	87.99	74.66	29.81
Research & Development	1.86	3.53	7.28	29.5	16.49	17.42
Other Operating Expenses	-1.07	-8.56	-	-	-	-
Operating Expenses	21.75	25.94	71.31	117.49	91.15	47.23
Operating Income	-20.49	-22.87	-42.84	-81.14	-63.68	-43.2
Interest Expense	-	-0.37	-41.33	-16.57	-12.45	-0.39
Interest & Investment Income	0.33	0.09	0.14	0.05	0.18	0.44
Currency Exchange Gain (Loss)	-0.12	-0.12	-0.04	-0.03	-0.01	0.07
Other Non Operating Income (Expenses)	-8.42	-7.45	12.41	-0.07	-0.3	0.3
EBT Excluding Unusual Items	-28.69	-30.71	-71.67	-97.74	-76.27	-42.78
Gain (Loss) on Sale of Investments	-	-	-	-	0.09	0.47
Gain (Loss) on Sale of Assets	-	35.5	-	-	-	-
Other Unusual Items	-1.48	19.13	-	-	-	-
Pretax Income	-30.17	23.92	-71.67	-97.74	-76.17	-42.3
Net Income	-30.17	23.92	-71.67	-97.74	-76.17	-42.3
Net Income to Common	-30.17	23.92	-71.67	-97.74	-76.17	-42.3
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	697.64%	320.45%	32.46%	27.72%	22.69%	28.43%
EPS (Basic)	-38.52	92.30	-1162.89	-2100.80	-2091.06	-1424.76
EPS (Diluted)	-38.52	92.30	-1162.89	-2100.80	-2091.06	-1424.76
Free Cash Flow	-24.24	-35.83	-29.38	-65.16	-48.99	-40.92
Free Cash Flow Per Share	-30.94	-138.28	-476.76	-1400.52	-1344.71	-1378.05
Gross Margin	34.04%	47.03%	46.06%	42.39%	42.68%	64.09%
Operating Margin	-552.68%	-350.20%	-69.33%	-94.61%	-98.95%	-686.71%
Profit Margin	-813.97%	366.25%	-115.97%	-113.98%	-118.36%	-672.45%
Free Cash Flow Margin	-653.76%	-548.71%	-47.55%	-75.98%	-76.11%	-650.41%
EBITDA	-20.94	-22.15	-36.56	-62.99	-54.94	-41.99
EBITDA Margin	-	-	-59.16%	-73.45%	-85.36%	-
D&A For EBITDA	-0.45	0.71	6.29	18.15	8.75	1.21
EBIT	-20.49	-22.87	-42.84	-81.14	-63.68	-43.2
EBIT Margin	-	-	-69.33%	-94.61%	-98.95%	-

Updated Aug 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q